Galderma Group AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	613	231	-57
Depreciation & Amortization	323	293	276
Stock-Based Compensation	64	68	-
Other Adjustments	115	134	68
Change in Receivables	-89	-208	47
Changes in Inventories	-88	-12	31
Changes in Accounts Payable	266	64	-66
Changes in Accrued Expenses	124	72	-13
Changes in Income Taxes Payable	-124	-90	-87
Changes in Other Operating Activities	-19	-64	-34
Operating Cash Flow	1,185	488	165
Operating Cash Flow Growth	142.83%	195.76%	-
Capital Expenditures	-113	-128	-121
Purchases of Intangible Assets	-41	-147	-32
Payments for Business Acquisitions	-	-50	-25
Other Investing Activities	-	-	4
Investing Cash Flow	-154	-326	-174
Long-Term Debt Issued	1,408	3,601	856
Long-Term Debt Repaid	-1,701	-5,777	-1,725
Net Long-Term Debt Issued (Repaid)	-293	-2,176	-869
Issuance of Common Stock	-	2,166	1,011
Repurchase of Common Stock	-363	-15	-
Net Common Stock Issued (Repurchased)	-363	2,151	1,011
Common Dividends Paid	-41	-	-
Other Financing Activities	-30	-32	-
Financing Cash Flow	-728	-58	142
Effect of Exchange Rate Changes on Cash and Cash Equivalents	20	-14	0
Net Cash Flow	323	90	134
Free Cash Flow	1,072	360	44
Free Cash Flow Growth	197.78%	718.18%	-
FCF Margin	20.45%	8.11%	1.07%
Free Cash Flow Per Share	4.52	1.51	0.19
Levered Free Cash Flow	689	-1,810	-940
Unlevered Free Cash Flow	1,164	615.63	-2,791